X-linked and cellular IAPs modulate the stability of C-RAF kinase and cell motility

Nature Cell Biology

Volumn 10, Issue 12, 2008, Pages 1447-1455

  Dogan, Taner ^a   Harms, Gregory S ^c   Hekman, Mirko ^b   Karreman, Christiaan ^b   Oberoi, Tripat Kaur ^a   Alnemri, Emad S ^d   Rapp, Ulf R ^b   Rajalingam, Krishnaraj ^a  

^a GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CARBOXY TERMINAL HEAT SHOCK COGNATE PROTEIN 70 INTERACTING PROTEIN; HEAT SHOCK PROTEIN 90; INHIBITOR OF APOPTOSIS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; SMALL INTERFERING RNA; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ARTICLE; CELL MIGRATION; CELL MOTILITY; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME METABOLISM; ENZYME STABILITY; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UBIQUITINATION;

INTRACISTERNAL A-PARTICLES;

EID: 57049153979     PISSN: 14657392     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncb1804     Document Type: Article

References (31)

1. Eckelman, B. P., Salvesen, G. S., & Scott, F. L. Human inhibitor of apoptosis proteins: Why XIAP is the black sheep of the family. EMBO Rep. 7, 988-994 (2006).
2. Salvesen, G. S. & Duckett, C. S. IAP proteins: Blocking the road to death's door. Nature Rev. Mol. Cell Biol. 3, 401-410 (2002).
3. Rajalingam, K., Schreck, R., Rapp, U. R., & Albert, S. Ras oncogenes and their downstream targets. Biochim. Biophys. Acta 1773, 1177-1195 (2007).
4. Wellbrock, C., Karasarides, M., & Marais, R. The RAF proteins take centre stage. Nature Rev. Mol. Cell Biol. 5, 875-885 (2004).
5. Srinivasula, S. M. & Ashwell, J. D. IAPs: What's in a name? Mol. Cell 30, 123-135 (2008).
6. Wright, C. W. & Duckett, C. S. Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function. J. Clin. Invest. 115, 2673-2678 (2005).
7. Vaux, D. L. & Silke, J. IAPs, RINGs and ubiquitylation. Nature Rev. Mol. Cell Biol. 6, 287-297 (2005).
8. Burstein, E. et al. A novel role for XIAP in copper homeostasis through regulation of MURR1. EMBO J. 23, 244-254 (2004).
9. Olayioye, M. A. et al. XIAP-deficiency leads to delayed lobuloalveolar development in the mammary gland. Cell Death Differ. 12, 87-90 (2004).
10. Alavi, A., Hood, J. D., Frausto, R., Stupack, D. G., & Cheresh, D. A. Role of Raf in vascular protection from distinct apoptotic stimuli. Science 301, 94-96 (2003).
11. Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. MAP kinase signalling pathways in cancer. Oncogene 26, 3279-3290 (2007).
12. Rapp, U. R., Rennefahrt, U., & Troppmair, J. Bcl-2 proteins: Master switches at the intersection of death signaling and the survival control by Raf kinases. Biochim. Biophys. Acta 1644, 149-158 (2004).
13. Tian, S. et al. Interaction and stabilization of X-linked inhibitor of apoptosis by Raf-1 protein kinase. Int. J. Oncol. 29, 861-867 (2006).
14. Klemke, R. L. et al. Regulation of cell motility by mitogen-activated protein kinase. J. Cell Biol. 137, 481-492 (1997).
15. Rajalingam, K. et al. Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration. Nature Cell Biol. 7, 837-843 (2005).
16. Srinivasula, S. M. et al. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 410, 112-116 (2001).
17. Vucic, D. Targeting IAP (inhibitor of apoptosis) proteins for therapeutic intervention in tumors. Curr. Cancer Drug Targets 8 110-117 (2008).
18. da Rocha, D. S. et al. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 65, 10686-10691 (2005).
19. Grbovic, O. M. et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc. Natl Acad. Sci. USA 103, 57-62 (2006).
20. McDonough, H. & Patterson, C. CHIP: A link between the chaperone and proteasome systems. Cell Stress Chaperones 8, 303-308 (2003).
21. Arndt, V., Rogon, C., & Hohfeld, J. To be, or not to be - molecular chaperones in protein degradation. Cell Mol. Life Sci. 64, 2525-2541 (2007).
22. Isaacs, J. S., Xu, W., & Neckers, L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 3, 213-217 (2003).
23. Schulte, T. W. et al. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway. Mol. Cell Biol. 16, 5839-5845 (1996).
24. Schulte, T. W., An, W. G., & Neckers, L. M. Geldanamycin-induced destabilization of Raf-1 involves the proteasome. Biochem. Biophys. Res. Commun. 239, 655-659 (1997).
25. Schneider, C. et al. Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc. Natl Acad. Sci. USA 93, 14536-14541 (1996).
26. Young, J. C., Agashe, V. R., Siegers, K., & Hartl, F. U. Pathways of chaperone-mediated protein folding in the cytosol. Nature Rev. Mol. Cell Biol. 5, 781-791 (2004).
27. Demand, J., Alberti, S., Patterson, C., & Hohfeld, J. Cooperation of a ubiquitin domain protein and an E3 ubiquitin ligase during chaperone/ proteasome coupling. Curr. Biol. 11, 1569-1577 (2001).
28. Noble, C. et al. CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation. Mol. Cell 31, 862-872 (2008).
29. Harlin, H., Reffey, S. B., Duckett, C. S., Lindsten, T., & Thompson, C. B. Characterization of XIAP-deficient mice. Mol. Cell Biol. 21 3604-3608 (2001).
30. Rajalingam, K. et al. IAP-IAP complexes required for apoptosis resistance of C. trachomatis-infected cells. PLoS Pathog. 2, e114 (2006).
31. Downward, J. Targeting RAS signalling pathways in cancer therapy. Nature Rev. Cancer 3, 11-22 (2003).